MINNEAPOLISMedtronic, Inc. and the National Comprehensive
Cancer network (NCCN) have announced that they are partnering in an
effort to shed light on a key concern of cancer patients and their
families: the best way to control cancer pain while preserving
patients quality of life.
Medtronic will provide up to $525,000 in a 3-year agreement to
support the development and expansion of the NCCN Oncology Outcomes
Database. The NCCN database will provide information about various
pain therapies administered under the networks cancer pain
treatment guidelines to facilitate comparisons of various techniques
and outcomes. Initial data are expected to be available by April 2001.
Medtronic, Inc., headquartered in Minneapolis, is a medical
technology company specializing in implantable and interventional
therapies, including the Medtronic SynchroMed implantable drug
infusion system that is used to deliver controlled doses of pain
medication intrathecally. The NCCN, established in 1995, is a
coalition of 17 leading US cancer treatment centers. Its Oncology
Practice Guidelines cover more than 90% of all cancers, and its
database includes information on more than 2,000 patients.
The NCCN database will compile information on patients pain and
quality of life before, during, and after cancer therapy. The
database will also collect and analyze data on how physician
practices adhere to the updated version of the NCCN guidelines for
the management of cancer pain and how patients benefit from the
provision of a range of pain therapies.